TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04050839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
Study: NCT00057512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4N
Description: Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
Study: NCT03238092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: oral estradiol during the late luteal phase.
Study: NCT00928616

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: margarine + plant sterol esters
Description: margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: margarine (placebo)
Description: non-sterol ester supplemented margarine
Study: NCT01437670

Intervention type: DRUG
Intervention: solifenacin 5mg, 10mg
Description: solifenacin 5mg, 10mg
Study: NCT03107780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT00450203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
Study: NCT01728896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-controlled oral refeeding
Study: NCT00443014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive, physical and social stimulation
Description: Sessions of 30 minutes daily five days a week for one year
Study: NCT02443857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChARMin
Description: The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChARMin
Description: The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChARMin
Description: The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChARMin
Description: The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
Study: NCT00450203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
Study: NCT02443857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChARMin
Description: The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChARMin
Description: The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
Study: NCT02317419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6927005
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
Study: NCT00450203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: 3 cycles of ECX chemotherapy post operatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: 3 cycles of ECX chemotherapy post operatively
Study: NCT02317419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6927005
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6927005
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6927005
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6927005
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT03942744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: on-line hemodiafiltration
Description: on-line postdilutional hemodiafiltration with high convective transport above 21 liters
Study: NCT03463681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabometyx
Description: cabozantinib 60 mg orally once daily
Study: NCT02729519

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAVI
Description: standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
Study: NCT00450203

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Description: 3 cycles of ECX chemotherapy post operatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: 3 cycles of pre-operative ECX chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: 3 cycles of pre-operative ECX chemotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Description: 3 cycles of pre-operative ECX chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
Study: NCT02729519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI
Description: standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
Study: NCT02631785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session.
Study: NCT00257192

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone oral capsules
Description: Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
Study: NCT00814840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads
Description: Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triple-site cardiac resynchronization
Description: Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
Study: NCT04513054

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood collection for genetic analysis
Description: Blood collection for genetic analysis
Study: NCT03960346

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablation with cryoenergy
Description: Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
Study: NCT01661595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg/day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg/day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg/day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg/day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule per day for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule per day for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule per day for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule per day for four weeks.
Study: NCT00302822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide
Description: from week 0 to 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine/tenofovir
Description: 1 pill/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir
Description: 1 pill/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir or efavirenz
Description: investigator choice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir or efavirenz
Description: investigator choice
Study: NCT03368144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearLumen II Peripheral Thrombectomy System
Description: Patients will be treated with the ClearLumen Peripheral Stent Graft System
Study: NCT02722785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise Training
Description: Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum \[1-RM\] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
Study: NCT04535115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Starting LRM (Lung Recruitment Maneuver)
Description: The LRM is performed first for 30 seconds (an insufflation pressure of 30 cmH2O for 30 seconds is applied). After a free interval of 3 minutes, the VtC is done during 1 minute. For VtC, tidal volume is increased from 6 to 8 ml.kg-1 of predicted body weight. Finally, after a new free interval of 3 minutes, the fluid challenge (consisting in fluid administration of 250 ml of Ringer Lactate) is started for 10 minutes (in aim to determine which patients are responders). This sequence is repeated every 30 minutes (maximum four times).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Starting VtC (Tidal Volume Challenge)
Description: The VtC is performed first for 1 minute. After a free interval of 3 minutes, the LRM is done for 30 seconds. Finally, after another free interval of 3 minutes, the fluid challenge is started for 10 minutes. This sequence is repe-tead every 30 minutes (maximum four times).
Study: NCT01044069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gene-modified T cells targeted
Description: Pts will undergo leukapheresis. The leukapheresis product will be washed \& frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, \& transduced with the 19-28z chimeric receptor \& expanded. All relapsed (either MRD+ or morphologic) \& refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo \& highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
Study: NCT01520441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
Study: NCT01458457

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized complementary medicine treatment
Description: An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized usual care
Description: Patients get usual care from their general practitioners/specialized physicians
Study: NCT01554020

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sugar Take Care
Description: One 1200 mg soft gel capsule administered 3X/day for duration of study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One 1200 mg soft-gel capsule administered 3X/day for duration of study
Study: NCT01298635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined phacotrabeculectomy
Description: trabeculectomy plus phacoemulsification with intraocular lens implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Study: NCT02219438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus
Description: An adductor canal catheter was inserted and ropivacaine 0.2% administered as hourly bolus doses of 8 mL each: one at time point zero and then on the hour for 7 additional doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus
Description: An adductor canal catheter was inserted and ropivacaine 0.2% administered as hourly bolus doses of 8 mL each: one at time point zero and then on the hour for 7 additional doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal
Description: An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
Study: NCT01058174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluconazole
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal amphotericin B
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caspofungin
Description: intravenous infusion
Study: NCT02219438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal
Description: An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
Study: NCT00137631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Many Men, Many Voices (3MV)
Description: Small-group, 6-session HIV prevention intervention for Black MSM.
Study: NCT03309332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER™ PFO Occluder
Description: Implantation of the AMPLATZER™ PFO Occluder in the PFO
Study: NCT04481425

Intervention type: OTHER
Group type: OTHER
Intervention: SMS intervention
Description: SMS intervention
Study: NCT01926041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline for tobacco smoking cessation
Description: The 16-week varenicline course conforms to real-practice government regulations in Taiwan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized counseling about both smoking cessation and weight control techniques
Description: The FIT2 program also offers behavior coaching in diet and physical activity to restrict post-cessation weight gain, which is not covered in conventional smoking cessation services.
Study: NCT01879618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin
Description: variable dosing regimen
Study: NCT04687202

Intervention type: OTHER
Intervention: follow up and record
Description: None additional intervention was applied to the subjects.
Study: NCT00746031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH analogue (Zoladex)
Description: 3.6mg subcutaneous implant. Monthly doses x 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH analogue (Zoladex)
Description: 3.6mg subcutaneous implant. Monthly doses x 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist-Cetrorelix
Description: Subcutaneous injection 3mg x3 over 7 days